-
公开(公告)号：US06922466B1
公开(公告)日：2005-07-26
申请号：US10090522
申请日：2002-03-04
申请人： Patrick Peterson , Bernhard Suhm , Yvette Tenney , Daniel McCarthy , Patrick McHugh , Peter Dick
发明人： Patrick Peterson , Bernhard Suhm , Yvette Tenney , Daniel McCarthy , Patrick McHugh , Peter Dick
CPC分类号： H04M3/5166 , H04M3/42221 , H04M3/5175 , H04M15/41 , H04M15/90 , H04M2215/016 , H04M2215/0164
摘要： A system for assessing an automated call routing system's performance is structured to present a caller calling into the automated call routing system with a call that includes an interactive voice response (IVR) portion and, at an option of the caller, an caller/agent dialog portion. The system operates to monitor calls coming into the automated call routing system and to record end-to-end calls from among the calls coming into the automated call routing system. A sequence of events for the recorded calls is transcribed, including events occurring in the IVR portion and in the caller/agent dialog portion, to identify predetermined call events of interest. The transcribed calls are analyzed to infer a complete event sequence of each of the recorded calls. From the analysis, parameters are calculated corresponding to cost effectiveness and usability of the automated call routing system, based at least in part upon information obtained by the caller during the IVR portion.
摘要翻译： 用于评估自动呼叫路由系统的性能的系统被构造成使呼叫者通过包括交互式语音响应（IVR）部分的呼叫来呈现给自动呼叫路由系统，并且在呼叫者的选择下，呼叫者/代理对话 一部分。 该系统用于监视进入自动呼叫路由系统的呼叫并记录来自进入自动呼叫路由系统的呼叫中的端到端呼叫。 所记录的呼叫的事件序列被转录，包括发生在IVR部分和呼叫者/代理对话部分中的事件，以识别感兴趣的预定呼叫事件。 分析转录的呼叫以推断每个记录呼叫的完整事件序列。 根据分析，至少部分地基于主叫方在IVR部分期间获得的信息来对应于自动呼叫路由系统的成本效益和可用性来计算参数。
-
2.发明申请公开(公告)号：US20210252125A1
公开(公告)日：2021-08-19
申请号：US17049245
申请日：2019-04-25
申请人： Patrick Leonard AHL , Akhilesh BHAMBHANI , Christopher Jon FARRELL , Patrick MCHUGH , Morrisa C. JONES , Daniel D. ROTH , Jessica R. SINACOLA , Justin STANBRO , Matthew P. WATSON , Emily WEN , Michael A. WINTERS , Merck Sharp & Dohme Corp.
发明人： Patrick Leonard Ahl , Akhilesh Bhambhani , Christopher Jon Farrell , Patrick McHugh , Morrisa C. Jones , Daniel D. Roth , Jessica R. Sinacola , Justin Stanbro , Matthew P. Watson , Emily Wen , Michael A. Winters
摘要： A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.
-
公开(公告)号：US20210177957A1
公开(公告)日：2021-06-17
申请号：US16769874
申请日：2018-12-04
申请人： William J. SMITH , Patrick MCHUGH , Michael Albert WINTERS , Julie M. SKINNER , Jian HE , Luwy MUSEY , Chitrananda ABEYGUNAWARDANA , Yadong Adam CUI , Michael J. KOSINSKI , Merck Sharp & Dohme Corp.
发明人： William J. Smith , Patrick McHugh , Michael Albert Winters , Julie M. Skinner , Jian He , Luwy Musey , Chitrananda Abeygunawardana , Yadong Adam Cui , Michael J. Kosinski
摘要： The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimens that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
-
4.发明申请ADAPTED LEPIDOPTERAN INSECT CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS 有权适应的LEPIDOPTERAN INSEC细胞用于生产重组蛋白公开(公告)号：US20160040124A1
公开(公告)日：2016-02-11
申请号：US14775154
申请日：2014-03-13
申请人： Carrie L. BALLIET , James M. WAGNER , Shyamsundar SUBRAMANIAN , David PAJEROWSKI , Danilo CASIMIRO , Jessica FLYNN , Jennifer GALLI , Patrick MCHUGH , Dawn HALL , Christopher DANIELS , Jennifer GIRARD , MERCK SHARP & DOHME CORP.
发明人： James M. Wagner , Shyamsundar Subramanian , David Pajerowski , Danilo Casimiro , John Balliet (DECEASED) , Jessica Flynn , Jennifer Galli , Patrick McHugh , Dawn Hall , Christopher Daniels , Jennifer Girard
IPC分类号： C12N5/07 , C12P21/00 , C07K14/005 , C12N7/00
CPC分类号： C12N5/0601 , C07K14/005 , C12N7/00 , C12N2500/60 , C12N2511/00 , C12N2770/36151 , C12P21/00
摘要： The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and/or maintained in reduced phosphate serum-free insect cell media.
摘要翻译： 本发明涉及在鳞翅目昆虫细胞杆状病毒感染期间相对于标准昆虫细胞培养条件增加培养物pH的用途，以使得能够生产重组基孔肯雅（CHIKV）病毒样颗粒（VLP）。 本发明还涉及衍生自昆虫细胞如Sf21的适应性昆虫细胞系，其可以在升高的培养pH下强壮生长，使用所述细胞系以正确构象重组产生pH敏感蛋白并增加重组蛋白相对于 标准昆虫细胞系。 在本发明的一些实施方案中，所述细胞可用于重组生产CHIKV VLP。 本发明还涉及一种用于生产pH适应的鳞翅目昆虫细胞系的方法。 在所述方法的一些实施方案中，产生和/或维持细胞系在减少的无磷酸血清无血清昆虫细胞培养基中。
-
5.发明申请公开(公告)号：US20140193876A1
公开(公告)日：2014-07-10
申请号：US14125695
申请日：2012-06-08
申请人： Aaron R. Goerke , Thomas Svab , Patrick McHugh , Kristin Valente
发明人： Aaron R. Goerke , Thomas Svab , Patrick McHugh , Kristin Valente
IPC分类号： C12N9/10
CPC分类号： C12N9/1077 , C07H21/04 , C07K14/34 , Y02P20/582
摘要： The present invention relates to the use of hydroxyapatite chromatography and multimodal chromatography, for punfication of diphtheria toxin, or a mutant form thereof, from a mixture, for example, a host cell fermentation mixture containing impurities such as host cell proteins and DNA. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of diphtheria toxin suitable for in vitro and in vivo applications.
摘要翻译： 本发明涉及使用羟基磷灰石色谱法和多峰色谱法，从混合物，例如含有诸如宿主细胞蛋白质和DNA等杂质的宿主细胞发酵混合物中对白喉毒素或其突变体形式进行治疗。 本发明还涉及将这种方法与用于纯化适于体外和体内应用的白喉毒素的其它分馏方法的多步骤方法的整合。
-
6.发明授权公开(公告)号：US11524076B2
公开(公告)日：2022-12-13
申请号：US16645068
申请日：2018-09-04
申请人： Merck Sharp & Dohme Corp. , Richard J. Porambo , Chitrananda Abeygunawardana , Luwy Kavuka Musey , Michael J. Kosinski , Yadong Adam Cui , Patrick McHugh , Janelle Konietzko
发明人： Richard J. Porambo , Chitrananda Abeygunawardana , Luwy Kavuka Musey , Michael J. Kosinski , Yadong Adam Cui , Patrick McHugh , Janelle Konietzko
摘要： The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
-
公开(公告)号：US09061121B2
公开(公告)日：2015-06-23
申请号：US13388695
申请日：2010-08-03
申请人： Niall Galloway , James Galloway , Patrick McHugh , Brian Collins
发明人： Niall Galloway , James Galloway , Patrick McHugh , Brian Collins
IPC分类号： A61M5/00 , A61M31/00 , A61F2/00 , A61B5/103 , A61B5/117 , A61M29/02 , A61B17/34 , A61M25/00 , A61M25/01 , A61B17/42 , A61B18/00 , A61B1/307 , A61B17/00
CPC分类号： A61M5/3287 , A61B1/307 , A61B5/1076 , A61B17/0482 , A61B17/3403 , A61B17/42 , A61B17/4241 , A61B2017/00805 , A61B2017/3405 , A61B2017/3407 , A61B2017/3411 , A61B2018/00517 , A61B2018/00523 , A61F2250/0067 , A61M25/0084 , A61M25/01 , A61M29/02 , A61M2202/06 , A61M2210/1089
摘要： Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents.
摘要翻译： 提供了用于向受试者靶向施用治疗剂的装置，系统和方法。 例如，提供了用于靶向尿道周围填充剂的装置，系统和方法。
-
公开(公告)号：US20120130282A1
公开(公告)日：2012-05-24
申请号：US13388695
申请日：2010-08-03
申请人： Niall Galloway , James Galloway , Patrick McHugh , Brian Collins
发明人： Niall Galloway , James Galloway , Patrick McHugh , Brian Collins
CPC分类号： A61M5/3287 , A61B1/307 , A61B5/1076 , A61B17/0482 , A61B17/3403 , A61B17/42 , A61B17/4241 , A61B2017/00805 , A61B2017/3405 , A61B2017/3407 , A61B2017/3411 , A61B2018/00517 , A61B2018/00523 , A61F2250/0067 , A61M25/0084 , A61M25/01 , A61M29/02 , A61M2202/06 , A61M2210/1089
摘要： Provided are devices, systems, and methods for targeted administration of therapeutic agents to a subject. For example, provided are devices, systems, and methods for targeting the administration of peri-urethral bulking agents.
摘要翻译： 提供了用于向受试者靶向施用治疗剂的装置，系统和方法。 例如，提供了用于靶向尿道周围填充剂的装置，系统和方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
